{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:16:44Z","timestamp":1787163404775,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-025-03480-5","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:50:40Z","timestamp":1771408240000},"page":"1653-1670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-3277","authenticated-orcid":false,"given":"Ahmed Z.","family":"Obeidat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Betz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Straus","family":"Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0250-415X","authenticated-orcid":false,"given":"Erica","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-8554","authenticated-orcid":false,"given":"Mark","family":"Gudesblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0535-3978","authenticated-orcid":false,"given":"Le H.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6248-3480","authenticated-orcid":false,"given":"Yang","family":"Mao-Draayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-0981","authenticated-orcid":false,"given":"Derrick","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-8234","authenticated-orcid":false,"given":"Jonathan D.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5514-9185","authenticated-orcid":false,"given":"Daniel","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2205-4233","authenticated-orcid":false,"given":"Ivan","family":"Bozin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-5542","authenticated-orcid":false,"given":"Jason P.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0153-4218","authenticated-orcid":false,"given":"Boyang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-9113","authenticated-orcid":false,"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Belviso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-8360","authenticated-orcid":false,"given":"Sai L.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"3480_CR1","doi-asserted-by":"publisher","unstructured":"Papiri G, D\u2019Andreamatteo G, Cacchio G, et al. Multiple sclerosis: inflammatory and neuroglial aspects. Curr Issues Mol Biol. 2023;45:1443\u201370. https:\/\/doi.org\/10.3390\/cimb45020094.","DOI":"10.3390\/cimb45020094"},{"key":"3480_CR2","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1007\/s10072-024-07416-9","volume":"45","author":"E Maida","year":"2024","unstructured":"Maida E, Abbadessa G, Cocco E, et al. Identifying definite patterns of unmet needs in patients with multiple sclerosis using unsupervised machine learning. Neurol Sci. 2024;45:3333\u201345. https:\/\/doi.org\/10.1007\/s10072-024-07416-9.","journal-title":"Neurol Sci"},{"key":"3480_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/20552173221104009","author":"TJ Titcomb","year":"2022","unstructured":"Titcomb TJ, Bao W, Du Y, Liu B, Snetselaar LG, Wahls TL. Association of multiple sclerosis with risk of mortality among a nationally representative sample of adults in the United States. Multiple Scler J Experim Trans Clin. 2022. https:\/\/doi.org\/10.1177\/20552173221104009.","journal-title":"Multiple Scler J Experim Trans Clin"},{"key":"3480_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211012835","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021. https:\/\/doi.org\/10.1177\/17562864211012835.","journal-title":"Ther Adv Neurol Disord"},{"key":"3480_CR5","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92:e1029\u201340. https:\/\/doi.org\/10.1212\/WNL.0000000000007035.","journal-title":"Neurology"},{"key":"3480_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058","volume":"13","author":"M Amin","year":"2023","unstructured":"Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2023;13:47\u201370. https:\/\/doi.org\/10.2217\/nmt-2021-0058.","journal-title":"Neurodegener Dis Manag"},{"key":"3480_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.799138","volume":"12","author":"BL Vollmer","year":"2021","unstructured":"Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis. Front Neurol. 2021;12:799138. https:\/\/doi.org\/10.3389\/fneur.2021.799138.","journal-title":"Front Neurol"},{"key":"3480_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2023.1234572","author":"S Thakolwiboon","year":"2023","unstructured":"Thakolwiboon S, Mills EA, Yang J, et al. Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration. Front Aging. 2023. https:\/\/doi.org\/10.3389\/fragi.2023.1234572.","journal-title":"Front Aging"},{"key":"3480_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577. https:\/\/doi.org\/10.3389\/fneur.2017.00577.","journal-title":"Front Neurol"},{"key":"3480_CR10","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1177\/1352458516630396","volume":"22","author":"A Scalfari","year":"2016","unstructured":"Scalfari A, Lederer C, Daumer M, Nicholas R, Ebers GC, Muraro PA. The relationship of age with the clinical phenotype in multiple sclerosis. Mult Scler. 2016;22:1750\u20138. https:\/\/doi.org\/10.1177\/1352458516630396.","journal-title":"Mult Scler"},{"key":"3480_CR11","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","volume":"79","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Zhao Y, Joseph J, Devonshire V. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008;79:1368\u201374. https:\/\/doi.org\/10.1136\/jnnp.2008.145805.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3480_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104866","volume":"77","author":"L Amezcua","year":"2023","unstructured":"Amezcua L, Livingston T, Hayward B, Zhou J, Williams MJ. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: a claims analysis of real-world data. Mult Scler Relat Disord. 2023;77:104866. https:\/\/doi.org\/10.1016\/j.msard.2023.104866.","journal-title":"Mult Scler Relat Disord"},{"key":"3480_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77:184\u201391. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3365.","journal-title":"JAMA Neurol"},{"key":"3480_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/1744666X.2021.1886924","volume":"17","author":"S Otero-Romero","year":"2021","unstructured":"Otero-Romero S, Sanchez-Montalva A, Vidal-Jordana A. Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Rev Clin Immunol. 2021;17:285\u2013300. https:\/\/doi.org\/10.1080\/1744666X.2021.1886924.","journal-title":"Expert Rev Clin Immunol"},{"key":"3480_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1197212","volume":"14","author":"G Macaron","year":"2023","unstructured":"Macaron G, Larochelle C, Arbour N, et al. Impact of aging on treatment considerations for multiple sclerosis patients. Front Neurol. 2023;14:1197212. https:\/\/doi.org\/10.3389\/fneur.2023.1197212.","journal-title":"Front Neurol"},{"key":"3480_CR16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","volume":"271","author":"SR Delgado","year":"2024","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol. 2024;271:1515\u201335. https:\/\/doi.org\/10.1007\/s00415-023-12007-3.","journal-title":"J Neurol"},{"key":"3480_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103921","volume":"63","author":"JA Nicholas","year":"2022","unstructured":"Nicholas JA, Gudesblatt M, Garabedian M, et al. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab. Mult Scler Relat Disord. 2022;63:103921. https:\/\/doi.org\/10.1016\/j.msard.2022.103921.","journal-title":"Mult Scler Relat Disord"},{"key":"3480_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12325-024-03047-w","volume":"42","author":"Y Mao-Draayer","year":"2025","unstructured":"Mao-Draayer Y, Bar-Or A, Balashov K, et al. Real-world safety and effectiveness of dimethyl fumarate in patients with MS: results from the ESTEEM phase 4 and PROCLAIM phase 3 studies with a focus on older patients. Adv Ther. 2025;42:395\u2013412. https:\/\/doi.org\/10.1007\/s12325-024-03047-w.","journal-title":"Adv Ther"},{"key":"3480_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","volume":"27","author":"D Ontaneda","year":"2019","unstructured":"Ontaneda D, Nicholas J, Carraro M, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord. 2019;27:101\u201311. https:\/\/doi.org\/10.1016\/j.msard.2018.09.038.","journal-title":"Mult Scler Relat Disord"},{"key":"3480_CR20","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1177\/13524585231205708","volume":"29","author":"BA Singer","year":"2023","unstructured":"Singer BA, Arnold DL, Drulovic J, et al. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2023;29:1795\u2013807. https:\/\/doi.org\/10.1177\/13524585231205708.","journal-title":"Mult Scler"},{"key":"3480_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34:185\u201396. https:\/\/doi.org\/10.1007\/s40263-020-00700-0.","journal-title":"CNS Drugs"},{"key":"3480_CR22","unstructured":"Obeidat AZ, Betz M, Farber S, et al. Comparative risk of severe infection with diroximel fumarate versus anti-CD20 monoclonal antibodies in multiple sclerosis: a study of real-world claims and mortality data. ACTRIMS Forum 2024; February 29 to March 2, 2024; West Palm Beach, FL 2024."},{"key":"3480_CR23","first-page":"469","volume":"8","author":"DA Ollendorf","year":"2002","unstructured":"Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8:469\u201376.","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"3480_CR24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/jcm14030873","volume":"14","author":"Y Treister-Goltzman","year":"2025","unstructured":"Treister-Goltzman Y, Menashe I, Nemet D. Adolescent obesity and Charlson comorbidity index in young adults. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14030873.","journal-title":"J Clin Med"},{"key":"3480_CR25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s12325-024-02902-0","volume":"41","author":"M Gudesblatt","year":"2024","unstructured":"Gudesblatt M, Bumstead B, Buhse M, et al. De-escalation of disease-modifying therapy for people with multiple sclerosis due to safety considerations: characterizing 1-year outcomes in 25 people who switched from ocrelizumab to diroximel fumarate. Adv Ther. 2024;41:3059\u201375. https:\/\/doi.org\/10.1007\/s12325-024-02902-0.","journal-title":"Adv Ther"},{"key":"3480_CR26","doi-asserted-by":"publisher","unstructured":"Ben-Zacharia AB, Feng JJ, Moss BP, et al. Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database. J Comp Eff Res. 2025;14:e240071. https:\/\/doi.org\/10.57264\/cer-2024-0071.","DOI":"10.57264\/cer-2024-0071"},{"key":"3480_CR27","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1007\/s00415-024-12384-3","volume":"271","author":"KA DiMauro","year":"2024","unstructured":"DiMauro KA, Swetlik C, Cohen JA. Management of multiple sclerosis in older adults: review of current evidence and future perspectives. J Neurol. 2024;271:3794\u2013805. https:\/\/doi.org\/10.1007\/s00415-024-12384-3.","journal-title":"J Neurol"},{"key":"3480_CR28","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1177\/1352458518800800","volume":"24","author":"EA Mills","year":"2018","unstructured":"Mills EA, Begay JA, Fisher C, Mao-Draayer Y. Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS. Mult Scler. 2018;24:1795\u2013807. https:\/\/doi.org\/10.1177\/1352458518800800.","journal-title":"Mult Scler"},{"key":"3480_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.7224\/1537-2073.2021-124","volume":"25","author":"L Freeman","year":"2023","unstructured":"Freeman L, Lucas A, Zhou J, Hayward B, Gough M, Livingston T. Outcomes and health care service use in adults 50 years or older with and without multiple sclerosis: a 6-year observational analysis. Int J MS Care. 2023;25:56\u201362. https:\/\/doi.org\/10.7224\/1537-2073.2021-124.","journal-title":"Int J MS Care"},{"key":"3480_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jns.2005.08.006","volume":"239","author":"C Tortorella","year":"2005","unstructured":"Tortorella C, Bellacosa A, Paolicelli D, et al. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. J Neurol Sci. 2005;239:95\u20139. https:\/\/doi.org\/10.1016\/j.jns.2005.08.006","journal-title":"J Neurol Sci"},{"key":"3480_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106552","volume":"100","author":"C Goldschmidt","year":"2025","unstructured":"Goldschmidt C, Glassman J, Ly B, et al. De-escalation of disease modifying therapies: a retrospective, observational single center study. Mult Scler Relat Disord. 2025;100:106552. https:\/\/doi.org\/10.1016\/j.msard.2025.106552.","journal-title":"Mult Scler Relat Disord"},{"key":"3480_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70042","volume":"32","author":"F Elberling","year":"2025","unstructured":"Elberling F, Mahler MR, Pontieri L, Sellebjerg F, Magyari M, Group DS. De-escalation of disease-modifying therapy in multiple sclerosis-a Danish nationwide cohort study. Eur J Neurol. 2025;32:e70042. https:\/\/doi.org\/10.1111\/ene.70042.","journal-title":"Eur J Neurol"},{"key":"3480_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40263-025-01164-w","volume":"39","author":"J Muller","year":"2025","unstructured":"Muller J, Sharmin S, Lorscheider J, et al. Treatment de-escalation in relapsing-remitting multiple sclerosis: an observational study. CNS Drugs. 2025;39:403\u201316. https:\/\/doi.org\/10.1007\/s40263-025-01164-w.","journal-title":"CNS Drugs"},{"key":"3480_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104583","volume":"72","author":"R Knapp","year":"2023","unstructured":"Knapp R, Hardtstock F, Wilke T, et al. Comparing the risk of serious infections in patients with and without MS: a German claims data analysis. Mult Scler Relat Disord. 2023;72:104583. https:\/\/doi.org\/10.1016\/j.msard.2023.104583.","journal-title":"Mult Scler Relat Disord"},{"key":"3480_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200164","author":"AM Langer-Gould","year":"2023","unstructured":"Langer-Gould AM, Smith JB, Gonzales EG, Piehl F, Li BH. Multiple sclerosis, disease-modifying therapies, and infections. Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/NXI.0000000000200164.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3480_CR36","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","volume":"35","author":"N Seery","year":"2021","unstructured":"Seery N, Sharmin S, Li V, et al. Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study. CNS Drugs. 2021;35:907\u201318. https:\/\/doi.org\/10.1007\/s40263-021-00810-3.","journal-title":"CNS Drugs"},{"key":"3480_CR37","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95:e1999\u20132008. https:\/\/doi.org\/10.1212\/WNL.0000000000010380.","journal-title":"Neurology"},{"key":"3480_CR38","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/ene.13537","volume":"25","author":"HK Olberg","year":"2018","unstructured":"Olberg HK, Eide GE, Cox RJ, et al. Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. Eur J Neurol. 2018;25:527\u201334. https:\/\/doi.org\/10.1111\/ene.13537.","journal-title":"Eur J Neurol"},{"key":"3480_CR39","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1177\/13524585211061343","volume":"28","author":"JA Cohen","year":"2022","unstructured":"Cohen JA, Bermel RA, Grossman CI, et al. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Mult Scler. 2022;28:1131\u20137. https:\/\/doi.org\/10.1177\/13524585211061343.","journal-title":"Mult Scler"},{"key":"3480_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104400","volume":"68","author":"J Peters","year":"2022","unstructured":"Peters J, Longbrake EE. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Mult Scler Relat Disord. 2022;68:104400. https:\/\/doi.org\/10.1016\/j.msard.2022.104400.","journal-title":"Mult Scler Relat Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03480-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03480-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03480-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:14:00Z","timestamp":1775726040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03480-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3480"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03480-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ahmed Z. Obeidat reports speaker fees\/advisory boards\/steering committees for Alexion Pharmaceuticals, Amgen, AstraZeneca, Banner Life Sciences, BD Biosciences, Biogen, Biologix Solutions, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, GW Pharmaceuticals, Horizon Therapeutics, Jazz Pharmaceuticals, Merck, Novartis, Sandoz, Sanofi-Genzyme, TG Therapeutics, and Viela Bio. Michelle Betz reports research support from and consultant\/speaker bureaus for Biogen, EMD Serono, Genentech, Genzyme, Horizon, Sanofi, and Teva. Rebecca Straus Farber reports research support from Biogen and Novartis; and consultant for Alexion, Genentech, Horizon, and TG Therapeutics. Erica Goff reports consultant for TG Therapeutics. Mark Gudesblatt reports speaker and consulting for Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi-Genzyme, Saol Therapeutics, and Teva Pharmaceuticals. Le H. Hua reports consulting fees from Alexion, EMD Serono, Genentech, Horizon, Novartis, and TG Therapeutics; served on scientific advisory boards for EMD Serono, Genentech, and Novartis; and non-promotional speaker honoraria for TG Therapeutics; received research funding paid directly to her institution from Genentech. Yang Mao-Draayer reports consulting fees from Biogen, Celgene, EMD Serono, Genzyme, Horizon, Janssen, Novartis, and Roche-Genentech; contracted research for Biogen, Chugai, NIH NINDS R01-NS080821, NIAID Autoimmune Center of Excellence UM1-AI110557, Novartis, and Sanofi-Genzyme; speaker bureaus for Biogen and Teva. Derrick Robertson reports research support from Anokion, Atara Biotherapeutics, Biogen, CorEvitas, EMD Serono, Genentech, GW Pharmaceuticals, Janssen, Novartis, PCORI, PRIME CME, Sanofi, and TG Therapeutics; consulting fees for Alexion, Amgen, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Greenwich Biosciences, Horizon, ImmPACTBio, Janssen, Mallinckrodt, Novartis, Sanofi, and TG Therapeutics; speaker fees from Alexion, Amgen, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Horizon, Janssen, PRIME CME, Sanofi, and TG Therapeutics. Jonathan D. Santoro research support from the National Institutes of Health, Race to Erase MS Foundation, and Thrasher Society; and consultant for Cycle Pharmaceuticals, TG Therapeutics, and UCB. Tony Wang, Daniel Gomes, Ivan Bozin, Jason P Mendoza, Boyang Bian, James B. Lewin, Nicholas Belviso, Sai L. Shankar are employees of Biogen and may hold stock in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective analysis was based on data collected as part of the Komodo Health Sentinel database, and therefore did not involve any new studies of human or animal subjects. This kind of retrospective study based on de-identified medical claims do not require Institutional Review Board approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}